New Developments in Triple-Negative Breast Cancer Therapies - Medpage Today
The recent virtual American Society of Clinical Oncology (ASCO) annual meeting featured several breast cancer clinical trials, including GeparNuevo, which looked at the addition of durvalumab (Imfinzi) to anthracycline- and taxane-based chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). In this third of four exclusive episodes, MedPage Today brought together three expert leaders in the field. Moderator Hope S. Rugo, MD, of the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, is joined by Jennifer Litton, MD, of the University of Texas MD Anderson Cancer Center in Houston, and William J. Gradishar, MD, of Northwestern University Feinberg School of Medicine in Chicago, for a virtual roundtable discussion about GeparNuevo and the future of TNBC therapy.
